This clearance establishes Scaida BrainCT-ICH as the first Canadian-developed AI solution for intracranial haemorrhage (ICH) triage to be cleared for clinical use in the United States...
This new system uses specialised software that can take into account real-time data to build an accurate 3D model of each individual patient’s anatomy...
Real-time AI-enabled 3D device visualisation powered by light instead of X-ray, improving navigation in complex endovascular procedures...
The clinic uses artificial intelligence to scan routine chest X-rays for subtle abnormalities that often go unnoticed in busy radiology settings...
Company expands portfolio of novel AI-powered clinical and operational solutions delivering proven impact at scale empowering breakthroughs in care through imaging...
The launch of this innovative digital solution, developed by mjn-neuro, a Spanish digital health company specialising in AI-driven neurotechnology, represents a significant milestone in Neuraxpharm’s mission to go beyond providing medication only, by offering patients and healthcare professionals complementary digital tools that enhance safety, autonomy, and quality of life....
The partnership provides industry partners with an integrated technology pipeline, from model training and scenario verification to deployment, aimed at advancing chronic-disease management into a new phase of intelligent, and high-efficiency service delivery....
TrackPSMA delivers a comparative assessment, quantifying disease changes from screening and follow-up scans, vastly improving a process that is often unstructured, manual, visually evaluated and inconsistently applied. ...
Becomes the first and only FDA-cleared seizure detection algorithm for pre-term neonates through adults, enabling rapid bedside detection, diagnosis, and treatment of non-convulsive seizures...
The AI system has analysed over 17,000 chest X-rays, identifying 960 lung nodules, of which 136 were categorised as high-risk...
